Comparative Efficacy And Safety Of Imeglimin Plus Metformin Versus Vildagliptin Plus Metformin In Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Patients: A Randomized, Open-Label Study - Nil

Government Medical College, Jammu0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年12月19日

试验速览

暂无简介。

•1.Age: =18-60 years (both male and female).
•2.Newly diagnosed type 2 diabetes mellitus (T2DM) patients (FBG =126mg/dl, PPBS = 200mg/dl with symptoms like polyuria, polydipsia and polyphagia, 2 hours plasma glucose OGTT = 200mg/dl and HbA1C = 6.5%) diagnosed within 6 months from starting of this study and attending the Endocrinology outpatient department (OPD).
•3.HbA1C 6.5-8 %
•4.Those who are willing to participate and give their consent shall be included in the study.

•1.Age <18 years and > 60 years
•2.Type 1 Diabetes Mellitus patients.
•3.T2DM patients having renal dysfunction with eGFR = 45ml/min.
•4.T2DM patients with hepatic impairment with child Turcotte Pugh (CTP) class C.
•5.Steroid induced T2DM/ Syndromic diabetes.
•6.Pregnant/ lactating women with diabetes.
•7.Patients not able to tolerate the therapy or presented with adverse drug reaction.
•8.Unwilling to participate

发起方